Barry Ladizinski - Concepedia

Author

Barry Ladizinski

AbbVie (United States)ORCID

Also Known As

B. Ladizinski, Barry Ladizinski

104

Publications

2.7K

Citations

H-Index

Concepts

All Affiliations

AbbVie (United States)Johns Hopkins University Probity Medical Research Brown University Northwestern University

About

Barry Ladizinski is an author at AbbVie (United States) specializing in medicine, dermatology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	740
2	Health Sciences	2	2	190
3	Public Health	2	2	164
4	Social Sciences	1	1	23
5	Anatomy	1	1	24

Barry Ladizinski

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, Henrique D. Teixeira, Eric L. Simpson, JAMA Dermatology	2021	451
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial Kristian Reich, Henrique D. Teixeira, Marjolein de Bruin‐Weller, The Lancet Atopic DermatitisMedicineModerate-to-severe Atopic DermatitisSkin AllergyClinical Dermatology	2021	366
Complications Associated With Use of Levamisole-Contaminated Cocaine: An Emerging Public Health Challenge Kachiu C. Lee, Barry Ladizinski, Daniel G. Federman Mayo Clinic Proceedings Substance AbuseSubstance UseHealth SciencesAddictionMedicine	2012	153
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Thomas Bieber, Journal of Allergy and Clinical Immunology	2021	119
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies Emma Guttman‐Yassky, Jacob P. Thyssen, Jonathan I. Silverberg, Journal of Allergy and Clinical Immunology	2022	56
Efficacy and Safety of Upadacitinib Treatment in Adolescents With Moderate-to-Severe Atopic Dermatitis Amy S. Paller, Barry Ladizinski, Pedro Mendes‐Bastos, JAMA Dermatology	2023	56
Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials Pedro Mendes‐Bastos, Barry Ladizinski, Emma Guttman‐Yassky, Journal of the American Academy of Dermatology	2022	55
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up) Andrew Blauvelt, Barry Ladizinski, Vimal H. Prajapati, Journal of the American Academy of Dermatology	2023	44
The history of atopic dermatitis Owen N. Kramer, Mark A. Strom, Barry Ladizinski, Clinics in Dermatology Atopic DermatitisSkin AllergyFood AllergiesDermatologyMedicine	2017	42
Sickle Cell Disease and Leg Ulcers Barry Ladizinski, Andrea Bazakas, Nisha Mistry, Advances in Skin & Wound Care ImmunohematologyRed Blood CellSickle Cell DiseaseAutoimmune DiseaseVasculitis	2012	37

Page 1